Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

228 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
MHC-binding peptides as immunotherapeutics for cancer.
Kobayashi H, Kennedy R, Lu J, Davila E, Celis E. Kobayashi H, et al. Immunol Invest. 2000 May;29(2):105-10. doi: 10.3109/08820130009062291. Immunol Invest. 2000. PMID: 10854176 No abstract available.
Classification of current anticancer immunotherapies.
Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G. Galluzzi L, et al. Oncotarget. 2014 Dec 30;5(24):12472-508. doi: 10.18632/oncotarget.2998. Oncotarget. 2014. PMID: 25537519 Free PMC article. Review.
Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis.
Reynolds SR, Celis E, Sette A, Oratz R, Shapiro RL, Johnston D, Fotino M, Bystryn JC. Reynolds SR, et al. J Immunol Methods. 2000 Oct 20;244(1-2):59-67. doi: 10.1016/s0022-1759(00)00254-4. J Immunol Methods. 2000. PMID: 11033019
A reproducible method for the enumeration of functional (cytokine producing) versus non-functional peptide-specific cytotoxic T lymphocytes in human peripheral blood.
Markovic SN, Nevala WK, Uhl CB, Celis E, McKean DJ. Markovic SN, et al. Clin Exp Immunol. 2006 Sep;145(3):438-47. doi: 10.1111/j.1365-2249.2006.03157.x. Clin Exp Immunol. 2006. PMID: 16907911 Free PMC article.
TAP-independent presentation of CTL epitopes by Trojan antigens.
Lu J, Wettstein PJ, Higashimoto Y, Appella E, Celis E. Lu J, et al. J Immunol. 2001 Jun 15;166(12):7063-71. doi: 10.4049/jimmunol.166.12.7063. J Immunol. 2001. PMID: 11390450
Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E, Celis E. Davila E, et al. J Immunol. 2000 Jul 1;165(1):539-47. doi: 10.4049/jimmunol.165.1.539. J Immunol. 2000. PMID: 10861094
However, peptide-based vaccines, in general, fail to elicit sufficiently strong CTL responses capable of producing therapeutic anti-tumor effects (i.e., prolongation of survival, tumor reduction). ...
However, peptide-based vaccines, in general, fail to elicit sufficiently strong CTL responses capable of producing therapeutic anti-tumor ef …
228 results
Jump to page
Feedback